Breast Cancer News

Skip to content
  • Home
  • What Is Breast Cancer?
    • Types of Breast Cancer
    • Breast Cancer Classification
    • Causes of Breast Cancer
      • Breast Tissue Density
      • Risk Factors
    • Signs and Symptoms
      • Breast Lump or Mass
      • Breast or Nipple Pain
      • Breast Swelling & Inflammatory Breast Cancer
      • Nipple or Breast Skin Alterations
      • Nipple Retraction
      • Skin Irritation or Dimpling
    • Diagnosis of Breast Cancer
    • Stages
    • Breast Cancer Statistics
    • Breast Cancer During Pregnancy
  • Treatment
    • Bone-directed Therapy
    • Chemotherapy
    • Surgery
      • Mastectomy
      • Breast Reconstruction
    • Radiation Therapy
    • Targeted Therapy
    • Ado-Trastuzumab Emtansine (Kadcyla)
    • Albumin-Bound Paclitaxel (Nab-Paclitaxel or Abraxane)
    • Anastrozole (Arimidex)
    • Capecitabine (Xeloda)
    • Cyclophosphamide (Clafen, Cytoxan, and Neosar)
    • Docetaxel (Taxotere)
    • Epirubicin Hydrochloride (Ellence)
    • Eribulin (Halaven)
    • Everolimus (Afinitor)
    • Exemestane (Aromasin)
    • Gemcitabine Hydrochloride (Gemzar)
    • Goserelin Acetate (Zoladex)
    • Ixabepilone (Ixempra)
    • Lapatinib Ditosylate (Tykerb)
    • Letrozole (Femara)
    • Lynparza (Olaparib)
    • Nerlynx (Neratinib)
    • Tecentriq
    • Experimental Treatments
      • GBR 1302
      • GMI-1359
  • Columns
    • A Lump in the Road
    • Journeying Toward the Pink Path
    • Protecting the Pecs
    • Chemo and Cocktails: A Young Survivor’s Guide
  • COVID-19 Info
    • COVID-19 Updates

Subscription Support

Home » Subscription Support

Click here to subscribe to the Breast Cancer News Newsletter!

Subscription Support

[contact-form-7 id=”16792″ title=”Subscription Support”]

Recent Posts

  • Enhertu conditional approval U.K.

    Enhertu Approved in UK for Inoperable, Advanced Breast Cancer

    February 22, 2021

  • IRX-2 Phase 2 trial

    Phase 2 Trial Will Test IRX-2 Combined With Keytruda, Chemotherapy for TNBC

    February 18, 2021

  • Tukysa, EU approval

    Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer

    February 15, 2021

Featured Post

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

June 30, 2020

Visit Breast Cancer News's profile on Pinterest.

FDA Approves Phesgo as Injection Treatment for HER2-positive Breast Cancers

July 1, 2020

Phesgo approved

FDA Approves Tukysa for Advanced HER2-positive Breast Cancer

May 7, 2020

FDA approval

Breast Cancer News

BioNews Services, LLC
3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363
  • Publishing Team
  • Leadership
  • Our Values
  • Terms of Service
  • Privacy Policy
  • Corrections Policy
  • Contact Us

Disclaimer:

Breast Cancer News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Copyright © 2013-2024 All rights reserved.
We use cookies to enhance your experience on our website. Privacy Policy Accept